Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity